Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On

Executive Summary

Release of several different safety announcements showcases US FDA Commissioner Gottlieb's efforts to quell potential public concerns with an active communication strategy. 
Advertisement

Related Content

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers
Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases
Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating
Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control
Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products
FDA examines cause of valsartan impurity
Gottlieb Issues Statement On Adverse Event Limitations – An Attempt To Quell Fears?
FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy
Outpatient Rx Safety Meeting To Spotlight Health Literacy, Provider Communication

Topics

Advertisement
UsernamePublicRestriction

Register

PS124531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel